Trading · Founded 1986 · www.pentokey.com · BSE 524210 · · ISIN INE702E01015
No Notes Added Yet
Business
Pentokey Organy (India) Ltd. is primarily engaged in the business of trading. The company acts as a trader and distributor of various chemicals, including organic and inorganic chemicals, solvents, paints, and allied products. Its core business model involves procuring chemicals from manufacturers or larger distributors and supplying them to various industrial clients, earning a margin on the difference between purchase and sale prices. The company's operations are largely focused on the Indian domestic market.
Revenue Mix
The company's primary business activity is chemical trading. Detailed segmentation by specific chemical types, end-user industries, or geographical breakdown beyond India is not readily available in public disclosures. Revenue is largely derived from the sale of various chemical products.
Industry
The company operates within the broader Trading sector, specifically in the chemical trading industry in India. This industry is generally fragmented and competitive, with numerous players ranging from small local distributors to large integrated chemical companies. Pentokey Organy appears to be a relatively smaller player in this segment, competing primarily on price, relationships, and timely supply. Its positioning is likely that of a niche or regional supplier rather than a dominant market leader.
MOAT
Pentokey Organy operates in a highly commoditized and competitive trading sector, making durable competitive advantages challenging to establish. Potential limited advantages may include established relationships with specific suppliers and customers, efficient working capital management, or localized distribution network efficiencies. However, the company does not appear to possess strong moats such as significant brand recognition, proprietary technology, strong network effects, or substantial cost leadership typically associated with larger, more diversified chemical manufacturers or distributors.
Growth Drivers
Growth in End-User Industries: Increased demand from key chemical-consuming sectors in India such as pharmaceuticals, agrochemicals, paints & coatings, textiles, and manufacturing.
Product Portfolio Expansion: Diversification into new types of chemicals or related products that cater to existing or new customer bases.
Enhanced Supply Chain & Logistics: Improvements in sourcing, inventory management, and distribution efficiency could lead to better margins and market reach.
Strategic Alliances: Forging stronger relationships or exclusive distribution agreements with manufacturers for specific products.
Risks
Commodity Price Volatility: Fluctuations in the prices of chemicals and raw materials can directly impact trading margins.
Intense Competition: The fragmented nature of the chemical trading market leads to margin pressure from numerous competitors.
Supply Chain Disruptions: Dependency on timely and cost-effective procurement from suppliers makes the company vulnerable to disruptions in global or domestic supply chains.
Credit Risk: Exposure to credit risk from customers, especially in the trading business where payment terms can vary.
Regulatory Changes: Changes in import/export policies, environmental regulations, or chemical safety standards can affect operations and costs.
Working Capital Management: Effective management of inventory and receivables is crucial for profitability and liquidity in a trading business.
Management & Ownership
Pentokey Organy (India) Ltd. is a promoter-driven company. As of recent disclosures, the promoter group holds a significant stake, indicating a closely held and managed business. Specific details on the individual promoters' backgrounds or the full management team's experience would require deeper scrutiny of annual reports and corporate filings. Like many smaller Indian companies, strategic direction and operational control are likely concentrated within the promoter family.
Outlook
Pentokey Organy operates in a fundamental, yet competitive, segment of the Indian economy. The bull case for the company hinges on its ability to capitalize on the sustained growth of India's industrial and manufacturing sectors, which are major consumers of chemicals. Efficient inventory management, strong supplier relationships, and disciplined working capital practices could enable stable, albeit modest, profitability. The bear case revolves around the inherent challenges of the trading business: thin margins, intense competition, sensitivity to chemical price fluctuations, and potential supply chain vulnerabilities. The company's relatively small scale means it has less leverage against larger players and may face difficulties in absorbing significant market shocks or regulatory changes. Its performance will largely be dictated by its operational efficiency and ability to navigate market cycles effectively.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 0 | 0 | 0 | 1 | 5 | 1 | -2 | -2 | 0 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 0 | 0 | 0 | 1 | 5 | 1 | -2 | -2 | 0 |
| Total Expenditure | 0 | 0 | 0 | 0 | 1 | 5 | 1 | -2 | -2 | -0 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 |
| Adjusted Earnings Per Share | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.8 | 0.2 | -0.5 | -0.2 | 0.3 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 122 | 85 | 1 | 5 | 9 | 2 | 0 | 0 | 4 | 4 | 1 | -3 |
| Other Income | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Total Income | 122 | 86 | 5 | 5 | 9 | 2 | 0 | 0 | 7 | 5 | 1 | -3 |
| Total Expenditure | 122 | 89 | 6 | 5 | 10 | 2 | 1 | 0 | 4 | 4 | 1 | -3 |
| Operating Profit | -0 | -3 | -2 | -0 | -1 | -0 | -0 | -0 | 3 | 1 | 0 | 0 |
| Interest | 3 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 14 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -4 | -7 | 10 | 0 | 0 | -0 | -0 | -0 | 3 | 1 | 0 | 0 |
| Provision for Tax | 0 | 2 | 1 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -4 | -9 | 10 | 0 | 0 | -0 | -0 | -0 | 3 | 1 | 0 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Profit After Adjustments | -4 | -9 | 10 | 0 | 0 | -0 | -0 | -0 | 3 | 1 | 0 | 0 |
| Adjusted Earnings Per Share | -7 | -14.2 | 15.3 | 0 | 0.5 | -0.7 | -0.4 | -0.3 | 5.1 | 1.4 | 0.4 | -0.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -75% | 0% | -13% | -38% |
| Operating Profit CAGR | -100% | 0% | 0% | 0% |
| PAT CAGR | -100% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -38% | -20% | 6% | 6% |
| ROE Average | 3% | 20% | 10% | -49% |
| ROCE Average | 3% | 20% | 10% | 12% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 5 | -4 | 6 | 6 | 6 | 6 | 5 | 5 | 8 | 9 | 9 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 12 | 12 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 33 | 13 | 4 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Total Liabilities | 49 | 21 | 16 | 6 | 7 | 6 | 6 | 5 | 9 | 10 | 10 |
| Fixed Assets | 9 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 2 |
| Total Current Assets | 37 | 10 | 15 | 6 | 7 | 6 | 5 | 5 | 8 | 9 | 8 |
| Total Assets | 49 | 21 | 16 | 6 | 7 | 6 | 6 | 5 | 9 | 10 | 10 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 0 | 12 | -3 | 8 | -2 | 1 | 1 | -0 | -0 | 1 | 0 |
| Cash Flow from Investing Activities | 0 | -0 | 16 | -1 | 2 | -1 | -1 | 0 | 0 | -1 | -0 |
| Cash Flow from Financing Activities | -1 | -12 | -13 | -7 | -0 | 0 | 0 | 0 | -0 | -0 | -0 |
| Net Cash Inflow / Outflow | -0 | -0 | -0 | 0 | -0 | -0 | 0 | -0 | 0 | -0 | 0 |
| Closing Cash & Cash Equivalent | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -7.01 | -14.25 | 15.32 | 0.02 | 0.5 | -0.7 | -0.38 | -0.26 | 5.06 | 1.39 | 0.39 |
| CEPS(Rs) | -6.07 | -13.25 | 16.33 | 0.12 | 0.5 | -0.7 | -0.38 | -0.25 | 5.07 | 1.4 | 0.39 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 8.01 | -6.23 | 9.09 | 9.12 | 9.63 | 8.91 | 8.54 | 8.29 | 13.36 | 14.77 | 15.08 |
| Core EBITDA Margin(%) | -0.57 | -3.53 | -682.36 | -12.91 | -8.72 | -43.94 | 0 | 0 | 19.51 | 9.8 | -25.97 |
| EBIT Margin(%) | -0.71 | -3.94 | 1594.2 | 6.66 | 3.8 | -28.21 | 0 | 0 | 73.39 | 20 | 30.19 |
| Pre Tax Margin(%) | -3.36 | -7.99 | 1310.61 | 1.04 | 3.32 | -28.23 | 0 | 0 | 72.74 | 19.85 | 29.71 |
| PAT Margin (%) | -3.36 | -9.79 | 1242.11 | 0.24 | 3.36 | -28.23 | 0 | 0 | 72.74 | 19.85 | 29.71 |
| Cash Profit Margin (%) | -2.91 | -9.1 | 1323.67 | 1.57 | 3.39 | -28.13 | 0 | 0 | 72.83 | 19.91 | 29.75 |
| ROA(%) | -8.95 | -25.62 | 52.06 | 0.1 | 4.76 | -6.78 | -4.15 | -3.04 | 44.81 | 9.47 | 2.55 |
| ROE(%) | -60.56 | -1602.18 | 1074.63 | 0.2 | 5.3 | -7.58 | -4.39 | -3.1 | 46.76 | 9.89 | 2.62 |
| ROCE(%) | -2.81 | -15.51 | 93.86 | 3.5 | 6.01 | -7.57 | -4.38 | -3.09 | 47.18 | 9.97 | 2.66 |
| Receivable days | 26.39 | 18.1 | 0 | 15.26 | 47.14 | 369.43 | 0 | 0 | 12.17 | 84.51 | 482.34 |
| Inventory Days | 38.02 | 29.41 | 128.71 | 7.53 | 7.04 | 0 | 0 | 0 | 17.2 | 0 | 144.64 |
| Payable days | 50.37 | 46.93 | 1622.07 | 35.95 | 18.99 | 124.43 | 0 | 0 | 24.62 | 23.3 | 44.32 |
| PER(x) | 0 | 0 | 0.82 | 878.03 | 26.36 | 0 | 0 | 0 | 8.19 | 40.26 | 80.86 |
| Price/Book(x) | 1.24 | -2.97 | 1.37 | 1.74 | 1.36 | 0.75 | 1.27 | 2.18 | 3.11 | 3.79 | 2.1 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.26 | 0.34 | 18.58 | 1.66 | 0.59 | 0.26 | 2425.35 | 0 | 4.93 | 6.74 | 18.11 |
| EV/Core EBITDA(x) | -91.48 | -9.55 | -9.25 | -18.39 | -8.92 | -0.92 | -9.4 | -43.91 | 6.71 | 33.61 | 59.92 |
| Net Sales Growth(%) | -1.53 | -29.79 | -99.11 | 517.42 | 97.51 | -83.2 | -99.94 | -100 | 0 | 0.71 | -81.21 |
| EBIT Growth(%) | -166.35 | -284.69 | 442.92 | -97.46 | 12.74 | -224.61 | 45.49 | 31.94 | 2062.03 | -72.56 | -71.63 |
| PAT Growth(%) | -107.06 | -103.21 | 207.53 | -99.88 | 2652.91 | -241.32 | 45.38 | 32.05 | 2042.2 | -72.52 | -71.86 |
| EPS Growth(%) | -107.06 | -103.21 | 207.53 | -99.88 | 2652.64 | -241.34 | 45.38 | 32.04 | 2041.89 | -72.52 | -71.86 |
| Debt/Equity(x) | 5.43 | -4.6 | 1.14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 1.1 | 0.74 | 4.06 | 12.35 | 7.84 | 11.72 | 38.45 | 92.03 | 15.6 | 36.93 | 24.5 |
| Quick Ratio(x) | 0.67 | 0.7 | 5.56 | 12.17 | 7.51 | 11.72 | 38.45 | 92.03 | 15.22 | 36.93 | 23.5 |
| Interest Cover(x) | -0.27 | -0.97 | 5.62 | 1.18 | 7.85 | -1319.47 | -363.06 | -816.5 | 112.42 | 131.22 | 63.95 |
| Total Debt/Mcap(x) | 4.38 | 1.55 | 0.83 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 73.03 | 73.03 | 73.03 | 73.03 | 73.03 | 73.03 | 73.03 | 73.03 | 73.03 | 73.03 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 |
| Public | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Public | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -75% | — | -13% | -38% |
| Operating Profit CAGR | -100% | — | — | — |
| PAT CAGR | -100% | — | — | — |
| Share Price CAGR | -38% | -20% | +6% | +6% |
| ROE Average | +3% | +20% | +10% | -49% |
| ROCE Average | +3% | +20% | +10% | +12% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 73.03 | 73.03 | 73.03 | 73.03 | 73.03 | 73.03 | 73.03 | 73.03 | 73.03 | 73.03 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 | 2.31 |
| Public | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Public | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.